On April 11, 2026, the 3rd Hospital-Enterprise Cooperation Event of the Guangzhou Research Hospital Alliance was held at Shangri-La Hotel, Guangzhou, under the theme of “Innovation-Driven Development of the Biomedical Industry from Emerging Sector to Pillar Industry”. As one of the sub-forums of the 2026 National Conference on Deepening Healthcare Reform Experience Promotion and China Health Development Conference, the event brought together about 400 participants, including officials from relevant provincial and municipal departments, leaders and research backbones of 18 alliance hospitals, as well as representatives from domestic and foreign biomedical enterprises, research institutes and industry associations.

A leading official from the Guangdong Provincial Health Commission stated that Guangdong has listed the biomedicine and health industry as one of the province’s ten strategic pillar industrial clusters. It has successively issued a series of policies such as the “38 Measures for Biomedicine”, special regulations for medical institution preparations, and guidelines for the transformation of scientific and technological achievements, supporting Guangzhou to set an example in clinical evaluation, ethical mutual recognition, research ward construction and other fields. It is hoped that the Guangzhou Research Hospital Alliance will continue to deepen the integration of healthcare and industry, and provide more replicable experience for the province and even the whole country.

A leading official from the Guangzhou Municipal People’s Government emphasized that as a national central city and the core engine of the Guangdong-Hong Kong-Macao Greater Bay Area, Guangzhou boasts a solid foundation for innovation, abundant clinical resources and prominent industrial advantages. Over the past two years, the alliance has achieved remarkable results in accelerating clinical trials, enhancing the efficiency of achievement transformation, facilitating precise hospital-enterprise matchmaking, and promoting the application of innovative drugs and medical devices. It is hoped that medical institutions and enterprise representatives will take this event as an opportunity to carry out precise docking and in-depth cooperation, make good use of the alliance’s open platform, promote two-way empowerment of healthcare undertakings and the biomedical industry, and enable more innovative achievements to benefit the people.

The event included keynote speeches and policy interpretation sessions, where several guests shared cutting-edge practices on achievement transformation, proof of concept, innovation platform construction and other topics. The Guangzhou Municipal Healthcare Security Bureau introduced relevant policies to further support the development of innovative drugs and medical devices; the Guangzhou Municipal Health Commission interpreted the Implementation Plan for Guangzhou’s “Top-up and Lead” Program on Real-World Research of Innovative Drugs and Medical Devices; and relevant research institutions delivered special speeches on “Real-World Research under the Policy of Cross-Border Use of Hong Kong and Macao Drugs and Medical Devices”. In the roundtable discussion, representatives from alliance hospitals, innovative drug and medical device enterprises and research institutes held in-depth dialogues on “Real-World Research Empowering Innovative Drugs and Medical Devices – From Data Evidence to Clinical Transformation and Medical Insurance Access”, providing valuable ideas for future policy breakthroughs and practical implementation.

The event also released the 3rd issue of the Hospital-Enterprise Cooperation Resource Handbook, which systematically showcases the cooperation achievements and resource lists of alliance hospitals and enterprises, offering a convenient tool for regular and precise matchmaking.

Statistics show that since its establishment two years ago, the Guangzhou Research Hospital Alliance has achieved the transfer and transformation of more than 500 intellectual property rights, with the annual growth rate of the transaction value of achievement transformation projects exceeding 40%. The average project approval time for clinical trials has been shortened by nearly 34%, and the startup cycle is controlled within 18 weeks, with the total number of hospital-enterprise cooperation projects exceeding 1,500. The average monthly procurement volume of innovative drugs and medical devices has increased by more than 100%. The scope of the “Cross-Border Use of Hong Kong and Macao Drugs and Medical Devices” has been expanded to 26 institutions and 128 products. The alliance has also signed a strategic cooperation framework agreement with the Chengdu Municipal Health Commission to jointly build a multi-center clinical research network. The alliance will continue to focus on the goal of “Four More Achievements” and contribute greater efforts to the high-quality development of Guangzhou’s biomedical industry and the construction of a Healthy China.

Source: Guangzhou Municipal Health Commission